Akers Biosciences Begins Selling Rapid Cholesterol Test through Distribution Agreement with First Check

THOROFARE, NJ--(Marketwired - Mar 28, 2017) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, has received an initial order for the Company's rapid cholesterol self-test from First Check Diagnostics, LLC ("First Check"), the exclusive distributor for this product in the United States, for sale under their popular "First Check" brand.
 
First Check products are sold through major retailers including, CVS, Rite Aid, Target, Kmart, Meijer, Giant Eagle, Stop & Shop, Giant and ShopKo.
 
Akers Bio's Tri-Cholesterol "Check" test is the only combined rapid test which provides an estimate of a person's Total cholesterol as well as their High Density Lipoprotein ("HDL") cholesterol levels - their 'good cholesterol'; thereby providing an estimate of a person's Low Density Lipoprotein ("LDL") levels - their 'bad cholesterol'. These features are essential to accurately differentiating between a person's 'good' and 'bad' cholesterol thereby making it a truly effective screening test for high cholesterol.
Read more: Akers Biosciences ( AKER )

Groupon Announces Fourth Quarter and Fiscal Year 2016 Results

2017-02-15 08:31 ET - News Release
 
Added 5.2 million net new customers and achieved double digit Gross Profit growth in North America for 2016
 
Fourth quarter revenue of $934.9 million, $3.1 billion for the full year
Fourth quarter gross billings of $1.7 billion, $6.1 billion for the full year
Fourth quarter net loss of $50.2 million, $183.3 million for the full year
Fourth quarter Adjusted EBITDA of $80.6 million, $178.1 million for the full year
Fourth quarter loss per share of $0.09; non-GAAP earnings per share of $0.07
Read more: Groupon Inc ( GRPN )

FDA Exempts Evoke from Requirement for Human Factor Validation Study

SOLANA BEACH, Calif., Feb. 15, 2017  -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced that it has received a letter from FDA exempting its late stage product, Gimoti™ from a Human Factors (HF) Validation study requirement prior to submission of a New Drug Application (NDA).
 
In February 2016, FDA published new guidance entitled “Applying Human Factors and Usability Engineering to Medical Devices”, which requires drug products classified as a drug/device combination, such as Gimoti, undergo evaluation that may require an HF Validation study as described in FDA’s Guidance. 
Read more: Evoke Pharma Inc ( EVOK )

Globex Intersects New Gold Zone at Francoeur Mine

ROUYN-NORANDA, QUEBEC--  Jan. 18, 2017) -GLOBEX MINING ENTERPRISES INC. (TSX:GMX)(FRANKFURT:G1M)(STUTTGART:G1M)(BERLIN:G1M)(MUNICH:G1M)(XETRA:G1M)(OTCQX:GLBXF) is please to inform shareholders of the results of a drill hole on our Francoeur Gold Mine Property, 25 km west of Rouyn-Noranda, Quebec.
 
Drill hole FS-16-35 intersected 4.64 gpt Au over 8 m from 99 to 107 m including 8.01 gpt Au over 4 m from 100 to 104 m (0.14 oz/t Au over 26.25 feet between 324.8 feet and 351.1 feet including 0.23 oz/t Au over 13.12 feet from 328.1 to 341.2 feet). The true width is approximated 55% of the intersection width. The gold intersection occurs at a vertical depth of approximately 90 m (295 ft) below surface in altered and fractured diorite and mafic volcanics with carbonate/silica/hematite alteration.
Read more: Globex Mining Enterprises ( GMX )

Marathon Deposit Drilling Intersects 25.33 g/t Au (uncut) over 14.0 meters with 310.35 g/t Au (uncut) over 1.0 meters, Valentine Lake Gold Camp

TORONTO, ON--(January 16, 2017) - Marathon Gold Corporation ("Marathon" or the "Company") (TSX: MOZ) is pleased to announce the very positive results from the remaining drill holes of the 2016 drilling campaign at the Marathon Deposit, Valentine Lake Gold Camp; including the spectacular 25.33 g/t Au (uncut) over 14.0 meters including 310.35 g/t Au (uncut) over 1.0 meter near surface in drill hole MA-16-154. In addition, wide intervals of high-grade gold were intersected in deeper sections of drill holes MA-16-153 to MA-16-156 and extended MA-15-034 with best deep intercepts included 3.03 g/t Au over 18.0 meters in MA-16-053, 2.64 g/t Au over 40.0 meters in MA-16-154, and 2.84 g/t Au over 31.0 meters in MA-16-156 (Figure 1).
Read more: Marathon Gold Corporation ( MOZ )

Videos / Webinars

View all videos